HHS Public Access

Author manuscript

Am J Med Case Rep. Author manuscript; available in PMC 2021 March 04.

Published in final edited form as:

Am J Med Case Rep. 2021 ; 9(3): 184–189. doi:10.12691/ajmcr-9-3-13.

Percutaneous Closure of Post-infarction and Iatrogenic Ventricular Septal Ruptures Using Amplatzer Occluder®: A Systematic Review

Pramod Theetha Kariyanna[1], **Ashkan Tadayoni**[2], **Amog Jayarangaiah**[3], **Sudhanva Hegde**[2], **Apoorva Jayaranagaiah**[4], **Isabel M. McFarlane**[2,*]

[1]Division of Interventional Cardiology, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Morningside/Beth Israel Hospitals, New York City, NY-10025, U.S.A.

[2]Department of Internal Medicine, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, U.S.A.

[3]Trinity School of Medicine, 925 Woodstock Road, Roswell, GA 30075, U.S.A.

[4]Department of Internal Medicine, Albert Einstein College of medicine/ Jacobi Medical Center, Bronx, N.Y., U.S.A.

Abstract

Ventricular septal rupture (VSR) is a rare complication of myocardial infarction (MI), open heart surgery, and cardiac-based procedures, such as septal myectomy and valve replacement. VSR is associated with high mortality rates and the reported 30-day survival rate is less than 10% without any interventional therapy. Hence, prompt diagnosis and aggressive medical treatment with appropriate surgical intervention are necessary to improve survival. Immediate surgical intervention which is the standard treatment of VSR has a mortality rate of 19-60%. Due to persistent high mortality rate and challenging management of VSR, alternatives to surgical repair has been proposed; transcatheter approach as a new alternative method has been used for the closure of post-surgery residual defects or as a bridge to surgery and in some cases as a definitive therapy instead of surgical repair. Amplatzer Occluder® (AO), a type of transcatheter closure devices, is an approved method of repairing congenital atrial septal defects and it is being used as an alternative method of treatment in VSR. In this systemic review, we assessed the cases of VSR who underwent septal repair by using AO. The study shows that the total mortality rate of percutaneous VSR repair with AO is 20% which is comparable to 19-60% rate of death in patients who undergo surgery. While early intervention is necessary to prevent biventricular dysfunction, immediate surgical intervention on soft and friable tissue surrounding the infarction increases the risk of residual shunt and reoperation. However, this study reveals that the mortality rate of primary percutaneous VSR closure within 7 days of VSR detection was 37 % which is significantly lower than 60% in surgical repair in the same period. In conclusion, given that the prevalence of residual leak in both interventions are similar and close to 20%, percutaneous VSR

*Corresponding author: Isabel.McFarlane@downstate.edu.

closure with AO device could be superior to the surgical repair as a primary intervention in unstable or high-risk surgical patients.

1. Introduction

Ventricular septal rupture (VSR) is a rare but well-known complication of myocardial infarction (MI); however, it has been also reported as a complication of open heart surgery and cardiac-based procedures, such as septal myectomy and valve replacement [1,2,3]. Studies indicate that VSR initially complicated MI at a rate of 1-2%, however, advancing the reperfusion therapy has significantly reduced the incidence to 0.2-0.3% in this cohort [4,5]. Despite this achievement, VSR is still associated with high mortality rates, and the reported 30-day survival rate is less than 10% without any interventional therapy [5,6]. Hence, prompt diagnosis and aggressive medical treatment with appropriate surgical intervention are necessary to improve survival [4].

The current American College of Cardiology and American Heart Association recommendation is immediate surgical repair for patients with VSR, regardless of the hemodynamic status [7]. However, the surgical repair outcome of VSR is still disappointing with the mortality rate of 19-60%, mainly due to the hemodynamic instability condition before the surgery following the ventricular dysfunction and left-to right shunt [5,8]. In addition, early intervention on soft and friable myocardial tissue surrounding the infarction increases the risk of residual shunt and reoperation [5]. Due to persistent high mortality rate and challenging management of post-MI VSR, alternatives to surgical repair have been proposed; transcatheter approach as a new alternative method has been used for the closure of post-surgery residual defects or as a bridge to surgery and in some cases as a definitive therapy instead of surgical repair [8].

Amplatzer Occluder® (AO), a type of transcatheter closure device, is an approved method of sealing congenital atrial septal defects [9]. The AO is a self-expandable double-disk device consisting of a polyester material (Nickel-Titanium) that develops occlusion and tissue growth. After locating the device on the ruptured wall, the first and second discs are deployed on the outer and inner aspects of the ruptured septum, respectively [10]. The AO sizes are available in a wide range from 3-38 mm corresponding to the septal defects. Even though thrombotic events following AO placement have been rarely reported, the complication could be serious [11]. Hence, starting proper antiplatelet therapy and regular echocardiographic evaluation are necessary, and if any thrombosis is detected anticoagulation therapy with close follow-up is required [12]. In this study, we assessed the literature describing the use of AO in repairing VSR following myocardial infarction and cardiac-based procedure to have a better understanding of the benefits, risks, and outcomes.

2. Materials and Methods

A comprehensive computer-based literature search of English language studies was performed, using PubMed, Google Scholar, CINAHL, Cochrane CENTRAL, and Web of Science databases, to identify the relevant literature. Our search keywords included cardiac septal rupture, ventricular septal rupture, ventricular septal defect, myocardial infarction,

cardiac-based procedure, septal ablation, Amplatzer Occluder®, transcatheter ventricular septal rupture closure, and percutaneous closure were used to determine cases of VSR who underwent percutaneous closure procedure. This extensive scoping study includes articles from May 1998 until September 2019. Relevant cases were selected by reviewing the reference list of each article. All non-English and non-human studies were excluded. Furthermore, all meta-analysis, review articles, and abstracts were excluded from this study. Data regarding demographic information, cause of free wall rupture, location of the perforation, size of Amplatzer, and complication of the percutaneous closure and outcome were reviewed and analyzed.

3. Results

Applying the keywords in database searching, we identified 1360 related studies. However, only 774 of them were qualified given the eligibility criteria and title. After reviewing the eligible article abstracts, 25 studies were selected. Subsequently, 12 case reports were selected for collecting the data and analysis by reviewing the full-text of the literature.

A total of 25 patients with the mean ± standard deviation (SD) age of 70.08 ± 12.04 years and male gender dominancy (52%) were identified (Table 1). VSR following acute myocardial infarction was related to 76% (19/25) of cases in this study. The other mechanisms involved in VSR were septal myomectomy and cardiac valve replacement (Table 2). The average size of VSR was 11.38 mm (range 5-32mm). In 20/25 (80%) of the cases AO was used as the primary device for management. The mean ± SD duration between the VSR development and AO placement for primary treatment was 25.73 ± 13.76 days. In the remaining 5/25 (20%) cases underwent surgical VSR repair. All 5/25 cases required percutaneous AO placement later to fix hemodynamic instability following persistent residual shunt. The mean ± SD duration between surgical repair and AO placement was 59 ± 39.47 days. Procedural success without procedure related complications and without significant residual leak was achieved in 68% (17/25) of the cases. In the remaining 32% (8/25) there were complications during the procedure or were diagnosed with persistent significant residual shunt. Among these 50% (4/8) of them survived with continued post-procedural medical management

The total number of deaths in this cohort was 20% (5/25). 80% (4/5) of them were related to peri-procedural worsening of leak and hemodynamic instability due to unsuccessful AO placement. In one case (1/5) the death was secondary to progressive renal failure even though the successful AO placement, proved by the autopsy, provided stable hemodynamic condition. Furthermore, 32% (8/25) of cases underwent AO placement within the first 7 days of diagnosis with a mortality rate of 37% (3/8). Therefore, the procedural success rate of VSR repair through percutaneous AO placement was 84% (21/25) with the total mortality rate of 20% (5/25) (Table 4). The average post-procedure follow-up in this cohort was about 15 months.

4. Discussion

Myocardial rupture is a rare but life-threatening complication of acute myocardial infarction, cardiac-based procedure, chest trauma, and open-heart surgery [1,2,9,13]. VSR, a type of myocardial rupture, is commonly related to MI and complicates 0.2-0.3% of the cases [4,5]. However, before introducing the reperfusion treatment, the incidence rate of post-infarction VSR was 10-fold higher compared to now [13]. Despite advancing the reperfusion procedure, VSR is still associated with a poor prognosis and high number of the deaths, exceeding 90% of patients who go untreated [5,6]. This high mortality rate might be due to prolonged left-to-right shunt following VSR which causes systemic hypoperfusion and ultimately multiple organ failure [14]. Hence, rapid diagnosis and appropriate surgical intervention is crucial for improving patient outcomes [4].

Transthoracic echocardiography with Doppler imaging is a sensitive and specific study in investigating VSR and estimating size of the defects [8,15]. The size and morphology of VSR are variable but generally it can be characterized as simple or complex. Simple defects are defined as a distinct similar level connection across the ventricular septum, and complex defects includes multiple small serpiginous tracts between the LV and RV [15]. Given the fact that new left to right shunt decreases the cardiac output and leads hemodynamically instability, stabilizing the patient to preserve the cardiac output is necessary to precede the intervention. While vasopressors are commonly used in patients with different types of shock, they can increase afterload which could worsen the left to right shunt. Hence IABP devices are used in unstable patients (Table 3) [16].

Surgery has been the gold standard treatment of VSR. Evidence-based guidelines recommend surgical intervention in the early stages of VSR development to shorten the duration of shunt and systemic hypoperfusion that ultimately prevents multiple organ failure and death [14]. However, the surgeons usually have to postpone the intervention for 3-4 weeks since early surgical repair on soft and friable tissue surrounding the infarction increases the chance of residual shunt and ultimately reoperation [5,14]. It explains why the mortality rate of VSR surgical repair varies but remains persistently high between 19 to 60% [8]. In addition, the studies show that the mortality rate could go up to 100% and surgery is ineffective in some of the cases with severe right ventricular dysfunction and very elderly patients [8]. *Arnaoutakis et al* recommends percutaneous transcatheter repair as an alternative treatment method in high-risk surgical patients with multiple risk factors, or unstable patients with signs of cardiogenic shock, multiple organ failure and in those with mechanical circulatory support needs [17].

The AO device is a self-expandable double-disk device and a connecting waist of 10 mm in length [13]. The AO consists of polyester material (nitinol) that develops in situ thrombosis of the waist to occlude the VSR. Even though the devices are retrievable for repositioning if the initial result is unsatisfactory, once the procedure is completed they are not retrievable [11,13].

In these systematic reviews, (8/25) 32% of AO placement procedures were complicated with significant residual leakage, hemolytic anemia, or groin hematoma. Although, 20% of cases

developed significant residual shunt, only one of them needed a new device placement four months later. The incidence of significant residual shunt is similar to the surgical repair residual leak which has been reported 20% [16]. This study showed that the total mortality rate of percutaneous VSR repair with AO is 20% which is comparable to 19-60% rate of death in patients who undergo surgery [8]. Mubarak et al reported that late surgical intervention (>7 days) has a better prognosis compared to emergent surgery (<7 days), and decreases the mortality rate from 60% to 18.4%. However, this study revealed that the mortality rate of primary percutaneous VSR closure within 7 days of VSR detection was 37 % which significantly lower than 60% in surgical repair [16]. Hence, while the prevalence of residual leak in both interventions are similar, percutaneous VSR closure with AO device might be superior to the surgical repair as a primary intervention in unstable or high-risk surgical patients. Furthermore, the long-term prognosis was reported well in our patients who survived and were discharged from the hospital. Average long-term follow-up for patients who survived to hospital discharge was about 15 months (Table 4). However, more investigations are required to extrapolate the data using AO device to repair VSR

5. Limitations

Devices for the VSR repair, it might be subject to selection bias. In addition, there are a limited number of cases that employed AO devices in order to repair VSR. All of the referenced studies were either case reports or case series without any control group to enhance the accuracy of the comparison. Importantly, some of the potential side effects of the AO device placement, such as device induced wall necrosis, and septic or thrombotic emboli formation might be disregarded given the limited studies on available AO devices.

6. Conclusion

VSR is an uncommon but fatal complication of MI and cardiac procedures. The mainstay treatment of VSR is surgical repair. While the ACC/AHA guideline recommends emergent surgical repair, most of the cases undergo delayed surgery to have a better outcome given the necrotic tissue surrounding the rupture is soft and friable, and it increases the risk of residual shunt and reoperation. It explains why the post-operation mortality rate is persistently high, especially in emergent surgical repair, less than 7 days. The current systematic review demonstrates that while the incidence rate of significant residual leak in VSR repair using AO device might be the same as surgical repair, the mortality rate of primary percutaneous VSR closure within 7 days of VSR detection is 37 % which is significantly lower than 60% in surgical repair. Therefore, employing AO in the VSR repair could be a potentially life-saving alternative, especially in patients who are unstable or very high risk to undergo surgery. However, further studies are required to evaluate the outcome and mortality rate of using AO in the VSR repair to provide us with more consistent and accuratedata.

Acknowledgements

This work is supported in part by Dr. Moro Salifu's efforts through NIH Grant # S21MD012474.

References

[1]. Aroney CN, Goh TH, Hourigan LA, Dyer W. Ventricular septal rupture following nonsurgical septal reduction for hypertrophic cardiomyopathy: treatment with percutaneous closure. Catheterization and cardiovascular interventions. 2004; 61(3): 411–4. [PubMed: 14988906]

[2]. Waciński P, Bilodeau L, Ibrahim R. Successful early percutaneous closure of acute ventricular septal rupture complicating acute myocardial infarction with Amplatzer ventricular septal occluder. Cardiology journal. 2007; 14(4): 411–4. [PubMed: 18651494]

[3]. Martinez MW, Mookadam F, Sun Y, Hagler DJ. Transcatheter closure of ischemic and post-traumatic ventricular septal ruptures. Catheterization and Cardiovascular Interventions. 2007; 69(3): 403–7. [PubMed: 17195200]

[4]. Birnbaum Y, Fishbein MC, Blanche C, Siegel RJ. Ventricular septal rupture after acute myocardial infarction. New England Journal of Medicine. 2002; 347(18): 1426–32.

[5]. Takahashi H, Arif R, Almashhoor A, Ruhparwar A, Karck M, Kallenbach K. Long-term results after surgical treatment of postinfarction ventricular septal rupture. European Journal of Cardio-Thoracic Surgery. 2015; 47(4): 720–4. [PubMed: 24994755]

[6]. Moreyra AE, Huang MS, Wilson AC, Deng Y, Cosgrove NM, Kostis JB, et al. Trends in incidence and mortality rates of ventricular septal rupture during acute myocardial infarction. The American journal of cardiology. 2010; 106(8): 1095–100. [PubMed: 20920645]

[7]. Maltais S, Ibrahim R, Basmadjian A-J, Carrier M, Bouchard D, Cartier R, et al. Postinfarction ventricular septal defects: towards a new treatment algorithm? The Annals of thoracic surgery. 2009; 87(3): 687–92. [PubMed: 19231370]

[8]. Shahreyar M, Akinseye O, Nayyar M, Ashraf U, Ibebuogu UN. Post-myocardial infarction ventricular septal defect: A comprehensive review. Cardiovascular Revascularization Medicine. 2018.

[9]. Kariyanna PT, Tadayoni A, Jayarangaiah A, Hegde S, Jayaranagaiah A, Salifu MO, et al. Employing Amplatzer Occluder® in Cardiac Free Wall Rupture Repair: A Scoping Study. Am J Med Case Rep. 2020; 8(9): 257–61. [PubMed: 32775627]

[10]. Madhkour R, Wahl A, Praz F, Meier B. Amplatzer patent foramen ovale occluder: safety and efficacy. Expert Review of Medical Devices. 2019; 16(3): 173–82. [PubMed: 30741039]

[11]. Roth CP, Qarmali M, Litovsky SH, Brott BC. Myocardial rupture after small acute myocardial infarction in the absence of coronary artery disease. Cardiovascular Pathology. 2018; 37: 26–9. [PubMed: 30223140]

[12]. Dar T, Yarlagadda B, Gunasekaran P, Lakkireddy D, Wiley MA. Successful Percutaneous Closure of Traumatic Right Ventricular Free Wall Rupture Using Amplatzer Vascular Plug Devices. J Atr Fibrillation. 2018; 11(2): 2095. [PubMed: 30505386]

[13]. Martinez MW, Mookadam F, Sun Y, Hagler DJ. Transcatheter closure of ischemic and post-traumatic ventricular septal ruptures. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions. 2007; 69(3): 403–7. [PubMed: 17195200]

[14]. Aggarwal M, Natarajan K, Vijayakumar M, Chandrasekhar R, Mathew N, Vijan V, et al. Primary transcatheter closure of post-myocardial infarction ventricular septal rupture using amplatzer atrial septal occlusion device: a study from tertiary care in South India. Indian Heart J. 2018; 70(4): 519–27. [PubMed: 30170647]

[15]. Amorosi NM, White A. Case of ventricular septal rupture following acute myocardial infarction. Ultrasound. 2020; 28(3): 196–201. [PubMed: 32831893]

[16]. Mubarik A, Iqbal AM. Ventricular Septal Rupture. 2018.

[17]. Arnaoutakis GJ, Zhao Y, George TJ, Sciortino CM, McCarthy PM, Conte JV. Surgical repair of ventricular septal defect after myocardial infarction: outcomes from the Society of Thoracic Surgeons National Database. Ann Thorac Surg. 2012; 94(2): 436–43; discussion 43-4. [PubMed: 22626761]

[18]. Giombolini C, Notaristefano S, Santucci S, Fortunati F, Savino K, Notaristefano F, et al. Transcatheter closure of postinfarction ventricular septal defect using the Amplatzer atrial septal defect occluder. Journal of cardiovascular medicine (Hagerstown, Md). 2008; 9(9): 941–5.

[19]. Ahmed J, Ruygrok PN, Wilson NJ, Webster MW, Greaves S, Gerber I. Percutaneous closure of post-myocardial infarction ventricular septal defects: a single centre experience. Heart, lung & circulation. 2008; 17(2): 119–23.

[20]. Mullasari AS, Umesan CV, Krishnan U, Srinivasan S, Ravikumar M, Raghuraman H. Transcatheter closure of post-myocardial infarction ventricular septal defect with Amplatzer septal occluder. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions. 2001; 54(4): 484–7. [PubMed: 11747185]

[21]. Szkutnik M, Kusa J, Bialkowski J. The use of two Amplatzer "Cribriform" Septal Occluders to close multiple postinfarction ventricular septal defects. Tex Heart Inst J. 2008; 35(3): 362–4. [PubMed: 18941645]

[22]. Lee EM, Roberts DH, Walsh KP. Transcatheter closure of a residual postmyocardial infarction ventricular septal defect with the Amplatzer septal occluder. Heart. 1998; 80(5): 522. [PubMed: 9930057]

[23]. Shabestari MM, Ghaderi F, Hamedanchi A. Transcatheter Closure of Postinfarction Ventricular Septal Defect: A Case Report and Review of Literature. J Cardiovasc Thorac Res. 2015; 7(2): 75–7. [PubMed: 26191397]

[24]. Viana-Tejedor A, Moreno R, Moreno M. Transcatheter closure of postinfarction ventricular septal rupture with the Amplatzer occluder. J Invasive Cardiol. 2008; 20(3): E79–E81. [PubMed: 18316838]

[25]. Wang X, Nie F, Ye N, Liu X, Yang S, Guo F, et al. Successful occlusion of ventricular septal rupture in myocardial infarction under the guidance of echocardiography. Journal of Cardiothoracic Surgery. 2019; 14(1): 133. [PubMed: 31277681]

[26]. Ishiyama M, Kurita T, Ishiura J, Yamamoto N, Sugiura E, Ito H, et al. Successful percutaneous treatment of recurrent post-infarction ventricular septal rupture using an Amplatzer duct occluder. Journal of Cardiology Cases. 2020; 21(1): 12–5. [PubMed: 31933699]

Table 1.

Demographic data and outcome for the studies reviewed

Information	Number
Total cases	25
Age	Mean 70.08 ± 12.04 Median 72.5 ± 12.04
Sex	Females 12 (48%) Males 13 (52%)
Primary and secondary percutaneous closure	20 (80%) and 5 (20%)
Cases of successful closure (primary and secondary device use)	21 (84%)
Subsequent death	5 (20%)

Table 2.

Etiology of ventricular septal rupture

Mechanism	Number (%)
Post-myocardial infarction	19 (76)
Non-surgical septal reduction	1 (4)
Septal myectomy	2 (8)
Traditional aortic valve replacement	2 (4)
Mitral valve replacement	1 (4)

Table 3.

Cases of percutaneous closure of ventricular septal rupture included in this study

	Year, Author	Etiology of the perforation	Location of the perforation	Post perforation signs and symptoms	Initial management once VSR was detected
1	2008, Giombolini [18]	Myocardial infarction	Sub-aortic valve VSD	Hemodynamic deterioration	IABP for 20 days
2	2007, Ahmed [19]	Myocardial infarction	Infero-apical VSD	Hypotension and dyspnea	IABP, CABG, and emergency surgical repair of the VSR
3	2007, Ahmed [19]	Myocardial infarction	Infero-basal VSD	Dyspnea and new systolic murmur	IABP and emergency surgical repair of the VSR
4	2007, Ahmed [19]	Myocardial infarction	Infero-basal VSD	New systolic murmur	Observation for 50 days
5	2007, Ahmed [19]	Myocardial infarction	Infero-septal VSD	New systolic murmur	CABG and observation for 4 weeks
6	2007, Ahmed [19]	Myocardial infarction	Infero-basal VSD	Hypotension and shock	IABP and stent placement
7	2001, Mullasari [20]	Myocardial infarction	Distal VSD	Dyspnea	Observation for 2 weeks
8	2008, Szkutnik [21]	Myocardial infarction	Apical VSD	Dyspnea and low cardiac output	IABP and inotropic drugs
9	1998, Lee [22]	Myocardial infarction	Mid-septal VSD	Hypotension, dyspnea, and new murmur	IABP, inotropic drugs, CABG, and urgent surgical VSR repair
10	2005, Wacinski [2]	Myocardial infarction	Infero-septal VSD	New murmur	Prompted percutaneous VSR closure
11	2004, Aroney [1]	Non-surgical septal reduction	VSD	Dyspnea, elevated JVD, and new murmur	Prompted percutaneous VSR closure
12	2008, Martinez [3]	Myocardial infarction	Infero-basal VSD	-	-
13	2008, Martinez [3]	Myocardial infarction	Inferior VSD	-	-
14	2008, Martinez [3]	Myocardial infarction	Infero-basal VSD	-	-
15	2008, Martinez [3]	Myocardial infarction	Apical VSD	-	-
16	2008, Martinez [3]	Myocardial infarction	Apical VSD	-	CABG and urgent surgical VSR repair
17	2008, Martinez [3]	Septal myectomy	Mid-basal VSD	Dyspnea and low cardiac output	-
18	2008, Martinez [3]	Septal myectomy	Mid-inferior VSD	-	-
19	2008, Martinez [3]	AVVR	Membranous VSD	-	-
20	2008, Martinez [3]	MVR	Sub-aortic valve VSD	-	-
21	2008, Martinez [3]	AVR	Sub-aortic valve VSD	-	-
22	2015, Shabestari [23]	Myocardial infarction	Apical VSD	Progressive dyspnea	IABP and CABG
23	2008, Tejedor [24]	Myocardial infarction	Anterior VSD	Dyspnea and low cardiac output	-
24	2019, Wang [25]	Myocardial infarction	Apical VSD	Dyspnea and palpitation	-
25	2019, Ishiyama [26]	Myocardial infsrction	Anterior VSD	Hypotension, JVD, and new murmur	IABP and urgent surgical VSR repair

VSR = Ventricular septal rupture, VSD = Ventricular septal defect, IABP = Intra-aortic balloon pump, CABG = Coronary artery bypass graft, JVD = Jugular venous distention, AVVR = Atrioventricular valve replacement, MVR = Mitral valve replacement, AVR = Aortic valve replacement.

Am J Med Case Rep. Author manuscript; available in PMC 2021 March 04.

Table 4.

Outcomes of percutaneous closure of ventricular septal rupture in this study

	Year, author	Size of Amplatzer Occluder (mm)	Significant residual shunt or complications related to Amplatzer Occluder placement	Proper intervention after Amplatzer placement complication	Length of stay	Follow-up
1	2008, Giombolini [18]	10	None	None	20 days	Death, 3 days later due to progressive renal failure despite adequate hemodynamic conditions. Autopsy showed good position of the device
2	2007, Ahmed [19]	18	None	None	13 days	Stable, 287 days later
3	2007, Ahmed [19]	12	Moderate residual leak	None	15 days	Death, 5 days later due to multi-organ failure
4	2007, Ahmed [19]	20	Hemolytic anemia due to very small residual leak. Large groin hematoma	Blood transfusion	-	Stable, 540 days later
5	2007, Ahmed [19]	20	Atrial flutter. Femoral arterial damage and large groin hematoma	Cardiac conversion. Femoral artery surgical repair	6 days	Stable, 270 days later
6	2007, Ahmed [19]	-	Device could not be placed successfully due to inability to cross the defect, likely related to tortuosity of the defect	The procedure was abandoned due to hemodynamic and rhythm instability	3 days	Death, within a day after the procedure
7	2001, Mullasari [20]	10	None	None	2 weeks	Stable, 30 days later
8	2008, Szkutnik [21]	35	None	None	30 days	Stable, 540 days later
9	1998, Lee [22]	10	None	None	1 week	Stable, 49 days later
10	2005, Wacinski [2]	20	None	Adjuvant prophylactic antibiotic therapy for 6 months	7 days	Stable, 360 days later
11	2004, Aroney [1]	20	Hemolytic anemia due to small high velocity shunt	Blood transfusion	10 days	Stable, 180 days later
12	2008, Martinez [3]	30	Moderate residual shunt	None	-	Yes, due to renal and CNS complications despite improved hemodynamics.
13	2008, Martinez [3]	20, 10	Moderate residual leak after first device placement	Second device placement 4 months later with small residual leak at f/u	-	Death, due to renal and CNS complications despite improved hemodynamics.
14	2008, Martinez [3]	12	None	None	-	Stable, 540 days later
15	2008, Martinez [3]	16	None	None	-	Stable, 1800 days later
16	2008, Martinez [3]	18	None	None	-	Stable, 540 days later
17	2008, Martinez [3]	18	None	None		Stable, 360 days later
18	2008, Martinez [3]	-	None	None	-	-
19	2008, Martinez [3]	14	None	None	-	Stable, 180 days later

	Year, author	Size of Amplatzer Occluder (mm)	Significant residual shunt or complications related to Amplatzer Occluder placement	Proper intervention after Amplatzer placement complication	Length of stay	Follow-up
20	2008, Martinez [3]	10-8	None	None	-	Stable, 180 days later
21	2008, Martinez [3]	6	None	None	-	-
22	2015, Shabestari [23]	20	None	None	-	-
23	2008, Tejedor [24]	35	Moderate residual leak and biventricular dysfunction	Continue IABP and inotropic therapy		Stable, 2160 days later
24	2019, Wang [25]	-	None	None	10 days	Death, 2 days later due to severe tricuspid regurgitation and biventricular dysfunction
25	2019, Ishiyama [26]	12	None	None	50 days	Stable, 360 days later

CNS = Central nervous system, IABP = Intra-aortic blood pump f/u: follow-up.